Last reviewed · How we verify

Bupivacaine FNB — Competitive Intelligence Brief

Bupivacaine FNB (Bupivacaine FNB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Pain Management / Regional Anesthesia.

marketed Local anesthetic Voltage-gated sodium channels Pain Management / Regional Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Bupivacaine FNB (Bupivacaine FNB) — Pacira Pharmaceuticals, Inc. Bupivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and conduction of nerve impulses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bupivacaine FNB TARGET Bupivacaine FNB Pacira Pharmaceuticals, Inc marketed Local anesthetic Voltage-gated sodium channels
Liposome bupivacaine Liposome bupivacaine Catherine Vandepitte, M.D. marketed Local anesthetic (liposomal formulation) Voltage-gated sodium channels
IV lignocaine bolus and infusion IV lignocaine bolus and infusion University of Auckland, New Zealand marketed Local anesthetic; Class IB antiarrhythmic agent Voltage-gated sodium channels
Intravenous Lidocaine infusion + Standard Anesthesia Intravenous Lidocaine infusion + Standard Anesthesia Instituto Mexicano del Seguro Social marketed Local anesthetic (sodium channel blocker) Voltage-gated sodium channels
Infiltration - EXPAREL Infiltration - EXPAREL Pacira Pharmaceuticals, Inc marketed Long-acting local anesthetic Voltage-gated sodium channels
Anesthetics, Local Anesthetics, Local University of Alberta marketed Local anesthetic Voltage-gated sodium channels
Levobupivacaine and Fentanyl Levobupivacaine and Fentanyl Hamad Medical Corporation marketed Local anesthetic with opioid analgesic combination Voltage-gated sodium channels; mu-opioid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

  1. University of California, San Diego · 3 drugs in this class
  2. Durect · 3 drugs in this class
  3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
  4. Wake Forest University Health Sciences · 3 drugs in this class
  5. Medical University of Vienna · 3 drugs in this class
  6. Imperial College London · 2 drugs in this class
  7. Hvidovre University Hospital · 2 drugs in this class
  8. Innocoll · 2 drugs in this class
  9. George Washington University · 2 drugs in this class
  10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bupivacaine FNB — Competitive Intelligence Brief. https://druglandscape.com/ci/bupivacaine-fnb. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: